NCT05119127 is a NA clinical trial of Alcon Vivity toric intra ocular lens in Cataract, sponsored by Kevin Barber.

Who is sponsoring NCT05119127?

NCT05119127 is sponsored by Kevin Barber.

What drugs are being tested in NCT05119127?

Interventions in NCT05119127: Alcon Vivity toric intra ocular lens.

Is NCT05119127 still recruiting?

NCT05119127 is currently completed. Last updated 12 November 2021.

Last reviewed 2021-11-12 · How we verify

NCT05119127

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.

Completed NA Last updated 12 November 2021

What this trial tests

NA trial testing Alcon Vivity toric intra ocular lens in Cataract in 35 participants. Completed in 19 August 2021.

Timeline

30 September 2020

Primary endpoint
5 May 2021

19 August 2021

Quick facts

Lead sponsor	Kevin Barber
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	30 September 2020
Primary completion	5 May 2021
Estimated completion	19 August 2021
Sites	1 location across United States

Drugs / interventions tested

Alcon Vivity toric intra ocular lens

Conditions studied

Cataract — all drugs for Cataract →

Sponsor

Kevin Barber

Who can join

45 and older, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to assess the rotational stability of the AcrySof IQ Vivity Extended Vision Toric IOL and Refractive Visual outcome.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Rotational stability and refractive outcomes of the DFT/DATx15 toric, extended depth of focus intraocular lens.
Barber KM, O'Connor S, Mackinder P, Chih A, et al · · 2023 · cited 5× · PMID 36894823 · DOI 10.1007/s10792-023-02673-7
Rotational stability and refractive outcomes of the DFT/DATx15 toric, extended depth of focus intraocular lens
Barber KM, O’Connor S, Mackinder P, Chih A, et al · · 2022 · DOI 10.21203/rs.3.rs-2143309/v1

Verify or expand the search:

Other recruiting trials for Cataract

Currently open trials in the same condition.

NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a · NA · recruiting
NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV · NA · recruiting
NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05119127 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kevin Barber
Last refreshed: 12 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05119127.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing